Latest News and Press Releases
Want to stay updated on the latest news?
-
Second-generation of AptameX, Achiko’s innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five yearsProduction of the second-generation AptameX kits to...
-
Achiko has received its first purchase order in Jakarta and Bali in Indonesia.The orders translate to 20,000 tests - while modest in size, the order is expected to pave the way to rapid adoption by...
-
After receiving product and registration approval from Indonesia’s Ministry of Health in August, Achiko is positioned to produce up to a million AptameX test kits in Q4 2021, and more if the supply...
-
Launch of pilot program in Indonesia for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service, Teman Sehat (“Health Buddy”).Purpose...
-
ZURICH, Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company...
-
ZURICH, Switzerland, July 13, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company currently developing technologies that seek to...
-
ZURICH, June 18, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) has successfully extended the subordinated convertible loan agreement of CHF 900,000 dated...
-
Wireless integration of AptameX Covid-19 test with Teman Sehat completedTeman Sehat’s open API allows for integration of third party testing platformsTeman Sehat provides results within 15 minutes,...
-
Wireless Integration of AptameX Covid-19 Test with Teman Sehat CompletedTeman Sehat’s Open API Allows for Integration of Third Party Testing PlatformsTeman Sehat Provides Results within 15 minutes,...
-
Production of First 1,000 AptameX Test Kits is Concluded in Singapore (initial capacity to test 10,000 patients per day).AptameX Delivers Sensitivity of 77% (95% CI: 75.94 - 79.24) at a High Industry...